INTERIM REPORT JANUARY - SEPTEMBER 2000

INTERIM REPORT JANUARY - SEPTEMBER 2000 *Turnover increased by 79% for comparable units to SEK 155.3 (86.6*) million. *Income after financial items increased by 167% to SEK 26.4 (9.9*) million. Increased investments in research and development, 26% (17*) of the turnover. *Ixion is consolidated as from July. This affected operating income by SEK -4.6 million. *Application for European approval of DUROLANE submitted at the beginning of October. *FDA's advisory body recommends approval of DEFLUX in USA. and 24,385,750 shares. ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/10/26/20001026BIT00560/bit0001.doc The full report http://www.bit.se/bitonline/2000/10/26/20001026BIT00560/bit0002.pdf The full report